127 related articles for article (PubMed ID: 10679652)
21. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
22. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
Amin A; Halabi S; Gelmann EP; Stadler W; Vogelzang N; Small E
Urol Oncol; 2004; 22(5):398-403. PubMed ID: 15464920
[TBL] [Abstract][Full Text] [Related]
23. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
Banu E; Banu A; Medioni J; Levy E; Thiounn N; Mejean A; Andrieu JM; Oudard S
Prostate; 2007 Oct; 67(14):1543-9. PubMed ID: 17705243
[TBL] [Abstract][Full Text] [Related]
24. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
26. [Low-dose cisplatin and UFT for hormone refractory prostate cancer].
Hoshi S; Ohyama C; Namiki S; Hagisawa S; Satoh M; Saito S; Ono K; Shirasaka T; Arai Y
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1773-8. PubMed ID: 12402428
[TBL] [Abstract][Full Text] [Related]
27. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
28. Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
Azuma H; Sakamoto T; Kiyama S; Ubai T; Kotake Y; Inamoto T; Takahara K; Nishimura Y; Segawa N; Katsuoka Y
Am J Clin Oncol; 2008 Apr; 31(2):188-94. PubMed ID: 18391605
[TBL] [Abstract][Full Text] [Related]
29. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
30. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):327-33. PubMed ID: 18707821
[TBL] [Abstract][Full Text] [Related]
31. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
32. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
Nakabayashi M; Xie W; Regan MM; Jackman DM; Kantoff PW; Oh WK
Cancer; 2006 Sep; 107(5):975-81. PubMed ID: 16862573
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
Hellerstedt B; Pienta KJ; Redman BG; Esper P; Dunn R; Fardig J; Olson K; Smith DC
Cancer; 2003 Oct; 98(8):1603-10. PubMed ID: 14534875
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: outcome results of RTOG 83-07.
Pilepich MV; Buzydlowski JW; John MJ; Rubin P; McGowan DG; Marcial VA
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):175-80. PubMed ID: 7721614
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer.
Wehbe TW; Stein BS; Akerley WL
Mayo Clin Proc; 1997 Oct; 72(10):932-4. PubMed ID: 9379696
[TBL] [Abstract][Full Text] [Related]
37. Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer.
Bonomi P; Pessis D; Bunting N; Block M; Anderson K; Wolter J; Rossof A; Slayton R; Harris J
Semin Oncol; 1985 Mar; 12(1 Suppl 1):36-9. PubMed ID: 3975650
[TBL] [Abstract][Full Text] [Related]
38. Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high-dose therapy.
Cruz JM; Muss HB; Brockschmidt JK; Evans GW
Semin Oncol; 1990 Dec; 17(6 Suppl 9):63-7. PubMed ID: 2259928
[TBL] [Abstract][Full Text] [Related]
39. [Therapy of hormone refractory prostate carcinoma with mitoxantrone. A clinical phase II study].
Otto T; Rembrink K; Goepel M; Krege S; Meyer-Schwiekerath M; Rübben H
Urologe A; 1996 Mar; 35(2):142-5. PubMed ID: 8650848
[TBL] [Abstract][Full Text] [Related]
40. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate.
Robinson MR; Smith PH; Richards B; Newling DW; de Pauw M; Sylvester R
Eur Urol; 1995; 28(4):273-83. PubMed ID: 8575493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
